Media Doctor Canada
Follow us on Twitter








"Good and bad news for rosiglitazone in diabetes study"

Medical Post

Source: Medical Post

Published: 09 Jan 2022

Category: Other

Rating: (2 stars)

what they said (Hover the mouse cursor over underlined words for more info)

TORONTO | Results from A Diabetes Outcome Progression Trial (ADOPT) were met with both excitement and caution following their presentation at the International Diabetes Federation's World Diabetes Congress in Cape Town in early December.

The ADOPT study, funded by GlaxoSmithKline, was designed to compare the ability of rosiglitazone (Avandia), metformin and glyburide monotherapy to maintain long-term glycemic control in 4,360 recently diagnosed type II diabetes patients....

The original article can be found at:

how did it rate? (more information)

Criteria Rating
Total Score 4 of 10
Availability of Treatment Not Satisfactory (?)
Novelty of Treatment Not Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Not Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Not Satisfactory (?)
Quantification of Benefits of Treatment Not Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of harms of treatment Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

Unfortunately this article did not provide any information about the type of study design and benefits and harm in terms of absolute risk reductions which make it difficult to draw any firm conclusions. Also there is no information on the comparative costs of rosiglitazone, metformin and glyburide.

The incidence of adverse events potentially related to volume expansion, other than congestive heart failure (i.e. pulmonary oedema and pleural effusions) has not been reported. Also, the clinical significance of the statistically higher rate of weight gain and fluid retention with rosiglitazone compared to metformin and glyburide in terms of mortality or morbidity over five year period of this study is not clear. It seems that something wrong is going on with rosiglitazone which longer prospective studies are needed to assess the impact and extent of the problem. There is no mention of the rate of hypoglycemia or other serious adverse events with 3 arms of this study. This story should have more clear emphasis on these points as its main massage for the readers.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada